Bulut N - Search Results

1

Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.

Bulut N, Aksoy S, Dizdar O, Dede DS, Arslan C, Dogan E, Gullu I, Ozisik Y, Altundag K. Bulut N, et al. Med Oncol. 2011 Dec;28 Suppl 1:S75-9. doi: 10.1007/s12032-010-9715-9. Epub 2010 Oct 21. Med Oncol. 2011. PMID: 20963641

2

Low bone mineral density value at the time of diagnosis of primary tumor in postmenopausal patients with operable breast cancer may increase bone metastasis risk.

Altundag K, Harputluoglu H, Bulut N. Altundag K, et al. Among authors: bulut n. Med Hypotheses. 2006;67(6):1465. doi: 10.1016/j.mehy.2006.05.026. Epub 2006 Jun 30. Med Hypotheses. 2006. PMID: 16814481 No abstract available.

3

Statins may decrease skeletal-related events in breast cancer patients with bone metastases.

Dincer M, Bulut N, Harputluoglu H, Altundag K. Dincer M, et al. Among authors: bulut n. Med Hypotheses. 2006;67(5):1146-7. doi: 10.1016/j.mehy.2006.05.009. Epub 2006 Jul 17. Med Hypotheses. 2006. PMID: 16844315

4

Anterior tongue metastasis from lung cancer.

Kurt M, Bulut N, Aksoy S, Kosemehmetoglu K, Kars A. Kurt M, et al. Among authors: bulut n. South Med J. 2006 Jul;99(7):784-5. doi: 10.1097/01.smj.0000224129.90177.2f. South Med J. 2006. PMID: 16866071 No abstract available.

5

Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.

Altundag K, Bulut N, Dizdar O, Harputluoglu H. Altundag K, et al. Among authors: bulut n. Breast Cancer Res Treat. 2006 Dec;100(3):329-30. doi: 10.1007/s10549-006-9250-8. Epub 2006 May 9. Breast Cancer Res Treat. 2006. PMID: 16897435 No abstract available.

6

Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression.

Altundag K, Tezcan ME, Ozen M, Karaahmet F, Bulut N. Altundag K, et al. Among authors: bulut n. Med Hypotheses. 2007;68(1):235. doi: 10.1016/j.mehy.2006.06.027. Epub 2006 Aug 14. Med Hypotheses. 2007. PMID: 16905272 No abstract available.

7

Does breast cancer associated with CHEK2 1100delC carry characteristics of basal phenotype?

Dede DS, Sari E, Bulut N, Altundag K. Dede DS, et al. Among authors: bulut n. Breast Cancer Res Treat. 2007 Jul;103(3):371. doi: 10.1007/s10549-006-9374-x. Epub 2006 Oct 25. Breast Cancer Res Treat. 2007. PMID: 17063273 No abstract available.

8

Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines.

Dizdar O, Dede DS, Bulut N, Altundag K. Dizdar O, et al. Among authors: bulut n. Breast Cancer Res Treat. 2008 Jan;107(2):303. doi: 10.1007/s10549-007-9551-6. Epub 2007 Mar 10. Breast Cancer Res Treat. 2008. PMID: 17351742 No abstract available.

9

Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer.

Bulut N, Harputluoglu H, Dizdar O, Altundag K. Bulut N, et al. J Neurooncol. 2008 Jan;86(2):241. doi: 10.1007/s11060-007-9447-7. Epub 2007 Jul 6. J Neurooncol. 2008. PMID: 17612792 No abstract available.

10

The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.

Altundag K, Bulut N, Sari E, Harputluoglu H. Altundag K, et al. Among authors: bulut n. Am J Surg. 2007 Aug;194(2):272-3. doi: 10.1016/j.amjsurg.2006.07.022. Am J Surg. 2007. PMID: 17618822 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

185 results

Search Page

Filters